Trends
Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.
Bereits Mitglied? Einloggen
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL ... Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in atopic dermatitis, asthma, and nasal polyposis; Libtayo in cutaneous squamous cell carcinoma; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal antibodies with Sanofi in immunology and cancer, and bispecific antibodies and antibody cocktails with other collaborators and independently. Mehr anzeigen
Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -30.38 | -4.57757620504 | 663.67 | 674.83 | 629.02 | 981592 | 657.21574495 | CS |
4 | -88.115 | -12.2143594791 | 721.405 | 748.29 | 629.02 | 952006 | 686.07365105 | CS |
12 | -91.12 | -12.5785121685 | 724.41 | 748.29 | 629.02 | 926951 | 691.70823216 | CS |
26 | -425.01 | -40.159690069 | 1058.3 | 1070 | 629.02 | 855714 | 765.79500889 | CS |
52 | -328.7 | -34.168754353 | 961.99 | 1211.1999 | 629.02 | 657556 | 865.10606979 | CS |
156 | -43 | -6.35821910719 | 676.29 | 1211.1999 | 538.01 | 622999 | 790.79802047 | CS |
260 | 206.78 | 48.4818644346 | 426.51 | 1211.1999 | 424.02 | 735752 | 678.68086265 | CS |
Keine Diskussionen Gefunden. |
Neuen Thread Erstellen |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen